GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Maze Therapeutics MAZE · USD

Health Care · US listing · 🇺🇸 United States

Compare

34.91

+2.11%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

—

FY2022FY2025

Net income

−$131.1m

FY2022FY2025

Free cash flow

−$112.7m

FY2022FY2025

Shareholders' equity

$355.0m

FY2022FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022
Revenue—$167.5m——
Gross profit−$2.4m$167.5m−$4.1m−$3.8m
Research and development$108.4m$83.5m$73.9m$88.2m
Operating income−$142.9m$57.6m−$98.6m−$111.0m
Net income−$131.1m$52.2m−$100.4m−$114.9m
Diluted earnings per share-3.051.19-2.29-57.47

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022
Total assets$397.1m$240.5m$71.5m$150.0m
Cash and short-term investments$341.9m$196.8m$29.2m$99.9m
Total liabilities$42.2m$43.6m$61.5m$48.5m
Debt$4.8m—$20.1m—
Shareholders' equity$355.0m$196.9m$10.1m$101.4m
Shares outstanding43m44m44m2m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022
Cash from operations−$111.9m$76.0m−$86.8m−$99.2m
Capital spending−$794,000−$1.1m−$441,000−$2.0m
Free cash flow−$112.7m$74.8m−$87.3m−$101.2m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue—$20.0m—————$2.5m
Gross profit—$19.6m−$499,000—−$649,000−$684,000−$705,000$2.5m
Operating income−$48.0m−$26.6m−$38.1m−$33.0m−$36.5m−$35.4m−$29.7m−$24.2m
Net income−$44.7m−$24.2m−$34.6m−$30.1m−$33.7m−$32.8m−$29.6m−$24.8m
Diluted earnings per share-0.76-0.41-0.80-0.70-0.78-0.76-0.68-0.57
Cash from operations−$15.0m−$39.0m−$27.0m−$24.0m−$30.0m−$29.0m−$22.0m−$23.0m
Total assets$531.6m$419.7m$397.1m$422.1m$303.5m$332.8m$240.5m$192.5m
Cash and short-term investments$411.1m$352.4m$341.9m$383.9m$264.5m$294.4m$196.8m$149.6m
Debt$4.9m$43.7m$4.8m$4.8m$4.7m$4.7m$4.6m$56.4m
Shareholders' equity$453.1m$341.7m$355.0m$379.4m$262.2m$292.1m$196.9m$99.4m

Financial ratios

Data as of 29 Oct 2026

FY2025FY2024FY2023FY2022
Gross margin—100.0%——
Operating margin—31.9%——
Net margin—31.2%——
Return on equity-36.9%26.5%-998.8%-113.3%
Return on assets-33.0%21.7%-140.4%-76.6%
Free cash flow yield-8.2%5.5%-6.2%-153.2%
Earnings growth-351.0%-152.0%-12.6%—
Current ratio15.50x9.76x2.09x5.11x
Debt to equity0.01x0.02x2.44x0.04x
Equity ratio89.4%81.9%14.1%67.6%
R&D as a share of sales—49.8%——
Buybacks as a share of market value1.9%-0.0%-2088.8%—

Growth per year

Compound annual rate

3 years5 years10 years
Operating income8.8%——
Net income4.5%——

Valuation history

At each fiscal year end

FY2025
Price to earnings-8.8

Market value over time

31 Jan 2025 to 28 Oct 2026, in USD

$31.9m$1.87bn

Share price return

Finished calendar years

2025
Return155%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.